Sichuan Hebang Biotechnology Corporation Limited (SHA: 603077)
China
· Delayed Price · Currency is CNY 2.130
-0.010 (-0.47%)
Nov 13, 2024, 3:00 PM CST
Sichuan Hebang Biotechnology Corporation Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 485.52 | 1,283 | 3,807 | 3,018 | 40.94 | 516.85 | Upgrade
|
| Depreciation & Amortization | 1,002 | 1,002 | 929.6 | 643.93 | 642.95 | 635.6 | Upgrade
|
| Other Amortization | 1.46 | 1.46 | 1.22 | 1.22 | 2.32 | 1.03 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.81 | -0.81 | -37.1 | 1.04 | -6.67 | 2.42 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.11 | 0.11 | 66.19 | 0.19 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -75.22 | -75.22 | -21.83 | -26.95 | -24.38 | 1.23 | Upgrade
|
| Provision & Write-off of Bad Debts | 14.17 | 14.17 | 11.75 | -4.02 | -5.5 | 13.29 | Upgrade
|
| Other Operating Activities | 570.54 | 57.73 | 65.41 | 101.52 | 83.37 | 56.78 | Upgrade
|
| Change in Accounts Receivable | 690.17 | 690.17 | -1,083 | 29.82 | -468.27 | -305.91 | Upgrade
|
| Change in Inventory | -2,349 | -2,349 | -1,179 | -278.93 | 678.3 | -269.21 | Upgrade
|
| Change in Accounts Payable | -624.13 | -624.13 | 112.33 | -313.4 | -526.31 | -490.84 | Upgrade
|
| Operating Cash Flow | -204.59 | 80.33 | 2,644 | 3,271 | 368.85 | 162.92 | Upgrade
|
| Operating Cash Flow Growth | - | -96.96% | -19.15% | 786.67% | 126.40% | -82.75% | Upgrade
|
| Capital Expenditures | -728.02 | -828.74 | -936.18 | -1,809 | -197.09 | -662.54 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.04 | 0.04 | 62.88 | 0.36 | 5.04 | 0.83 | Upgrade
|
| Cash Acquisitions | - | -66.19 | - | - | -2.41 | -643.92 | Upgrade
|
| Divestitures | 157.32 | 157.32 | 4 | 17.91 | - | - | Upgrade
|
| Investment in Securities | -264.79 | -165.05 | 57.81 | -15.76 | -56 | -55.3 | Upgrade
|
| Other Investing Activities | -38.92 | 120.39 | 4.25 | 10.08 | 40.09 | 84.56 | Upgrade
|
| Investing Cash Flow | -874.37 | -782.23 | -807.24 | -1,796 | -210.38 | -1,276 | Upgrade
|
| Long-Term Debt Issued | - | 1,806 | 1,750 | 1,270 | 1,920 | 1,743 | Upgrade
|
| Total Debt Issued | 3,017 | 1,806 | 1,750 | 1,270 | 1,920 | 1,743 | Upgrade
|
| Long-Term Debt Repaid | - | -1,673 | -1,308 | -2,089 | -1,635 | -1,065 | Upgrade
|
| Total Debt Repaid | -1,572 | -1,673 | -1,308 | -2,089 | -1,635 | -1,065 | Upgrade
|
| Net Debt Issued (Repaid) | 1,446 | 133.22 | 442.29 | -819.46 | 285.23 | 677.85 | Upgrade
|
| Repurchase of Common Stock | -500.37 | -500.37 | - | -179.93 | -120.07 | - | Upgrade
|
| Common Dividends Paid | -83.45 | -463.6 | -197.83 | -77.98 | -92.74 | -71.1 | Upgrade
|
| Other Financing Activities | -1,139 | -112.85 | 760.52 | 458 | 6.03 | -239.68 | Upgrade
|
| Financing Cash Flow | -276.69 | -943.6 | 1,005 | -619.36 | 78.45 | 367.06 | Upgrade
|
| Foreign Exchange Rate Adjustments | -12.57 | 5.47 | 21.86 | -10.55 | 26.22 | 9.29 | Upgrade
|
| Net Cash Flow | -1,368 | -1,640 | 2,864 | 844.33 | 263.14 | -737.1 | Upgrade
|
| Free Cash Flow | -932.6 | -748.4 | 1,708 | 1,462 | 171.76 | -499.62 | Upgrade
|
| Free Cash Flow Growth | - | - | 16.86% | 750.99% | - | - | Upgrade
|
| Free Cash Flow Margin | -10.13% | -8.48% | 13.10% | 14.64% | 3.26% | -8.37% | Upgrade
|
| Free Cash Flow Per Share | -0.11 | -0.09 | 0.20 | 0.17 | 0.02 | -0.06 | Upgrade
|
| Cash Income Tax Paid | 406.52 | 200.02 | 1,399 | 908.82 | 221.56 | 244.99 | Upgrade
|
| Levered Free Cash Flow | -492.2 | -773.46 | 1,510 | 1,251 | 1,062 | 33.75 | Upgrade
|
| Unlevered Free Cash Flow | -465.48 | -758.23 | 1,542 | 1,300 | 1,113 | 69.4 | Upgrade
|
| Change in Net Working Capital | 1,124 | 1,852 | 1,763 | -182.11 | -338.12 | 306.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.